Literature DB >> 11493434

Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction.

B S Youn1, Y J Kim, C Mantel, K Y Yu, H E Broxmeyer.   

Abstract

Chemokines play a pivotal role in regulating leukocyte migration as well as other biological functions. CC chemokine receptor 9 (CCR9) is a specific receptor for thymus-expressed CC chemokine (TECK). It is shown here that engagement of CCR9 with TECK leads to phosphorylation of Akt (protein kinase B), mitogen-activated protein kinases (MAPKs), glycogen synthase kinase--3 beta (GSK-3 beta), and a forkhead transcription factor, FKHR, in a human T-cell line, MOLT4, that naturally expresses CCR9. By means of chemical inhibitors, it is shown that phosphoinositide-3 kinase (PI-3 kinase), but not MAPK, is required for CCR9-mediated chemotaxis. Akt, GSK-3 beta, FKHR, and MAPK have been previously implicated in cell survival signals in response to an array of death stimuli. When MOLT4 cells, which expressed Fas as well as CXCR4, were stimulated with cycloheximide (CHX), an agonistic anti-Fas antibody, or a combination of these, the cells rapidly underwent apoptosis. However, costimulation of MOLT4 cells with TECK or stromal derived factor--1 significantly blocked CHX-mediated apoptosis, whereas stimulation only with TECK partially blocked Fas-mediated apoptosis. Concomitant with this blocking, cleavage of poly (adenosine 5'-diphosphate--ribose) polymerase and activation of caspase 3 were significantly attenuated, but the expression level of FLICE inhibitory protein c-FLIP(L), which had been shown to be regulated by CHX, was unchanged. This demonstrates that activation of CCR9 leads to phosphorylation of GSK-3 beta and FKHR and provides a cell survival signal to the receptor expressing cells against CHX. It also suggests the existence of a novel pathway leading to CHX-induced apoptosis independently of c-FLIP(L). (Blood. 2001;98:925-933)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493434     DOI: 10.1182/blood.v98.4.925

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.

Authors:  Sangjun Lee; Eileen L Heinrich; Lily Li; Jianming Lu; Audrey H Choi; Rachel A Levy; Jeffrey E Wagner; M L Richard Yip; Nagarajan Vaidehi; Joseph Kim
Journal:  Mol Oncol       Date:  2015-05-12       Impact factor: 6.603

2.  Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice.

Authors:  Barbara Cassani; Eduardo J Villablanca; Francisco J Quintana; Paul E Love; Adam Lacy-Hulbert; William S Blaner; Tim Sparwasser; Scott B Snapper; Howard L Weiner; J Rodrigo Mora
Journal:  Gastroenterology       Date:  2011-09-16       Impact factor: 22.682

3.  CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.

Authors:  Baijun Li; Zhiwei Wang; Yonglong Zhong; Jiao Lan; Xiangwei Li; Hui Lin
Journal:  Med Oncol       Date:  2015-02-18       Impact factor: 3.064

4.  Association between decreased CXCL12 and CCL25 expression and increased apoptosis in lymphoid tissues of cynomolgus macaques during SIV infection.

Authors:  Shulin Qin; Yongjun Sui; Michael A Murphey-Corb; Todd A Reinhart
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

5.  CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.

Authors:  Erica L Johnson; Rajesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard; Shailesh Singh
Journal:  J Ovarian Res       Date:  2010-06-17       Impact factor: 4.234

6.  Role of eotaxin-1 signaling in ovarian cancer.

Authors:  Vera Levina; Brian M Nolen; Adele M Marrangoni; Peng Cheng; Jeffrey R Marks; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis.

Authors:  Huanhuan Joyce Chen; Robert Edwards; Serena Tucci; Pengcheng Bu; Jeff Milsom; Sang Lee; Winfried Edelmann; Zeynep H Gümüs; Xiling Shen; Steven Lipkin
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

8.  Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.

Authors:  Jie Hui Li; Martin S Kluger; Lisa A Madge; Lian Zheng; Alfred L M Bothwell; Jordan S Pober
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

9.  A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells.

Authors:  Pengcheng Bu; Kai-Yuan Chen; Joyce Huan Chen; Lihua Wang; Jewell Walters; Yong Jun Shin; Julian P Goerger; Jian Sun; Mavee Witherspoon; Nikolai Rakhilin; Jiahe Li; Herman Yang; Jeff Milsom; Sang Lee; Warren Zipfel; Moonsoo M Jin; Zeynep H Gümüş; Steven M Lipkin; Xiling Shen
Journal:  Cell Stem Cell       Date:  2013-05-02       Impact factor: 24.633

Review 10.  Multiple roles for chemokines in the pathogenesis of SIV infection.

Authors:  Todd A Reinhart; Shulin Qin; Yongjun Sui
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.